Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 11:28 PM ET

Biotechnology

Company Overview of Kolltan Pharmaceuticals, Inc.

Company Overview

Kolltan Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, an antibody targeting the ErbB3 RTK, which is in Phase I clinical trials for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT RTK inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs. Kolltan Pharmaceuticals, Inc. was founde...

300 George Street

Suite 530

New Haven, CT 06511

United States

Founded in 2007

37 Employees

Phone:

203-773-3000

Fax:

203-773-1300

Key Executives for Kolltan Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 60
Co-Founder and Chairman of the Board
Age: 50
Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist and Director
Age: 70
Chief Financial & Business Officer and Senior Vice President
Age: 49
Senior Vice President of Translational Medicine & Product Development
Age: 49
Compensation as of Fiscal Year 2015.

Kolltan Pharmaceuticals, Inc. Key Developments

Kolltan Pharmaceuticals Appoints Frank Karbe to its Board of Directors

Kolltan Pharmaceuticals, Inc. announced the election of Frank Karbe, former Chief Financial Officer of Exelixis, to Kolltan’s Board of Directors. Frank Karbe most recently served as Executive Vice President and Chief Financial Officer of Exelixis, where he implemented and executed financing strategies that resulted in raising over $2 billion.

Kolltan Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:00 PM

Kolltan Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:00 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Gerald McMahon, Chief Executive Officer, President and Director.

Kolltan Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Kolltan Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Meso Scale Technologies, LLC United States
Micromet, Inc. United States
Dynamis Therapeutics, Inc. United States
Alice Therapeutics, Inc. United States
Acologix, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 8, 2014
Xetrios Therapeutics, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kolltan Pharmaceuticals, Inc., please visit www.kolltan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.